Myosite orbitaire associée à un traitement par ipilimumab
- 1 June 2013
- journal article
- case report
- Published by Elsevier BV in Annales de Dermatologie et de Vénéréologie
- Vol. 140 (6-7), 448-451
- https://doi.org/10.1016/j.annder.2013.02.029
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatmentHealth and Quality of Life Outcomes, 2012
- Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancerPharmacological Research, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV MelanomaClinical Cancer Research, 2009
- What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?The Oncologist, 2009
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal CancerJournal of Immunotherapy, 2005
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Journal of Clinical Oncology, 2005
- Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic MelanomaJournal of Immunotherapy, 2004